Edition:
United States

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

50.20USD
25 May 2018
Change (% chg)

$-0.85 (-1.67%)
Prev Close
$51.05
Open
$51.20
Day's High
$52.65
Day's Low
$50.15
Volume
90,926
Avg. Vol
244,865
52-wk High
$54.45
52-wk Low
$11.80

Select another date:

Tue, May 8 2018

BRIEF-Atara Biotherapeutics Reports Q1 Loss Per Share $1.05

* ATARA BIOTHERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

BRIEF-Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration

* ATARA BIOTHERAPEUTICS EXPANDS T-CELL IMMUNOTHERAPY COLLABORATION TO ADVANCE NEXT-GENERATION CAR T TECHNOLOGIES IN ONCOLOGY, AUTOIMMUNE AND OTHER DISEASES Source text for Eikon: Further company coverage:

BRIEF-Atara Biotherapeutics prices public offering of stock at $35 per share​

* ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Atara Biotherapeutics Files For Potential Mixed Shelf Offering

* ATARA BIOTHERAPEUTICS INC FILES FOR A POTENTIAL MIXED SHELF OFFERING; SIZE UNDISCLOSED - SEC FILING ‍​ Source text (http://bit.ly/2CKPbcB) Further company coverage:

BRIEF-Atara Says Commenced Underwritten Public Offering Of $150 Mln Shares Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

BRIEF-Atara Biotherapeutics Posts Q4 Loss Of $1.15 Per Share

* ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

BRIEF-Atara Biotherapeutics Says CFO Intends To Retire In April 2018

* ATARA BIOTHERAPEUTICS ANNOUNCES CHIEF FINANCIAL OFFICER INTENTION TO RETIRE IN APRIL 2018

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS

BRIEF-Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics

* CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING Source text : ( http://bit.ly/2m1PfiG ) Further company coverage:

BRIEF-Atara Biotherapeutics Announces Proposed Offering Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

Select another date: